Outcomes in Solid-Organ Transplant Recipients After the First Dose of Either SARS-CoV-2 mRNA Vaccine

摘要

Because immunosuppressed individuals have been largely excluded from SARS-CoV-2 vaccine trials, little is known about vaccine safety and efficacy in this population. In two studies, investigators report serologic responses and safety in solid-organ transplant (SOT) recipients (median time from transplant, 6 years) after receiving one dose of either mRNA vaccine.